Introduction

Adult Populations at High Risk of

Severe COVID-19
Immunocompromising Conditions That May
Result in Suboptimal COVID-19 Vaccine
Response
Case Study 1
Case Study 2
Clinical Spectrum of COVID-19
Major Risk Factors for Severe COVID-19
Influences Whether to Treat or Not
Treatment Options for Nonhospitalized
Adults at High Risk of Severe COVID-19
Summary of COVID-19 Treatments
Therapeutic Management of Nonhospitalized
Adults With COVID-19
Therapeutic Decision Aid for Outpatients
Ages 12+ Years
Practical Considerations for Outpatient
Therapies
Nirmatrelvir Use During the Omicron Surge
Ritonavir-Boosted Nirmatrelvir
Safety – EPIC-HR Trial
Remdesivir
Phase 3 PINETREE study
Molnupiravir
Phase 3 MOVe-OUT Study
Isolation and Precaution for
Immunocompetent Patients
With COVID-19
Isolation and Precaution for
Immunocompetent Patients
With COVID-19 (cont)
COVID-19 Isolation Resources
Therapies Not Recommended for Use in
Nonhospitalized Adults With COVID-19
Medications Without Clinically Relevant
Interactions With Ritonavir-Boosted
Nirmatrelvir
Medications to Temporarily Withhold During
Ritonavir-Boosted Nirmatrelvir Treatment
Medications That Have Clinically Relevant
DDIs With
Ritonavir-Boosted Nirmatrelvir
Management Strategies for Drug-Drug
Interactions
Conclusion